<DOC>
	<DOCNO>NCT00503204</DOCNO>
	<brief_summary>This Phase I , open-label , multi-centre study design ass safety tolerability Cediranib combination lomustine patient primary recurrent malignant brain tumour .</brief_summary>
	<brief_title>Phase I : Cediranib Combination With Lomustine Chemotherapy Recurrent Malignant Brain Tumour</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>Primary recurrent malignant brain tumour lomustine would standard therapy diagnosis &amp; stage Patients receive 2 previous systemic chemotherapy regimes Life Expectancy &gt; 12 week Patients must least 3 month completion cranial radiation therapy History poorly control high blood pressure Recent major surgery prior entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>cancer</keyword>
	<keyword>tumor</keyword>
	<keyword>advance solid tumour</keyword>
	<keyword>glioblastoma</keyword>
	<keyword>malignant brain tumour</keyword>
</DOC>